Checked.be
Active
BE 0508.599.605Public limited company
EYED PHARMA
Rue Louis Plescia 9 ·4102 Seraing, Belgium· 13 yrs active
Sector: NACE 72101
(72101)
Conclusion
The computed 12-month bankruptcy probability of EYED PHARMA is 0.3% (very low). The company has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
Based on State Gazette and CBE data.
Key figures
| Active | 13 yrs |
| Board | 13 |
| Locations | 1 |
| Publications | 67 |
Bankruptcy probability (12 mo)
0.3%
Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector
−Lower-risk legal form
−Long track record
−
Statistical estimate based on public sources — not credit advice nor a finding of fact. How do we compute this?
Risk Assessment
0 / 100
Low riskTrust signals
Established
Founded in 2012 — 13 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).
Administrative Flags
No administrative flags
Financial overview
Financials being processed
NBB has 10 filing(s) on record for this company — latest fiscal year 2024 (volledig). The annual accounts are being processed.
Filings on record
| Fiscal year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2024 | volledig | 28-07-2025 | 2025-00334949 |
| 31-12-2023 | volledig | 17-07-2024 | 2024-00269634 |
| 31-12-2022 | volledig | 28-06-2023 | 2023-00169377 |
| 31-12-2021 | volledig | 23-08-2022 | 2022-20305814 |
| 31-12-2020 | volledig | 31-08-2021 | 2021-60200314 |
| 31-12-2019 | volledig | 31-08-2020 | 2020-48000239 |
| 31-12-2018 | micro | 23-07-2019 | 2019-38100294 |
| 31-12-2017 | micro | 31-08-2018 | 2018-60700274 |
| 31-12-2016 | micro | 29-09-2017 | 2017-64900289 |
| 31-12-2015 | volledig | 02-08-2016 | 2016-39700570 |
Directors & mandates
Current directors & mandates
-
Current03-07-2025 → present
-
NOSHAQ SALegal entityDirector· perm. rep.: Eric BRANDTState Gazette act 25146507 (18-11-2025)Current03-07-2025 → present
-
Current23-04-2025 → present
-
Current15-12-2024 → present
-
Fund+Legal entityDirector· perm. rep.: Lawrence VAN HELLEPUTTEState Gazette act 23434913 (23-11-2023)Current24-01-2023 → present
2 events
- 23-11-2023 Appointed· Director
- 24-01-2023 Appointed· Director
-
Current15-05-2019 → present
-
Current10-07-2018 → present
-
Current13-12-2016 → present
-
Current13-12-2016 → present
2 events
- 03-07-2025 Mandate renewed· Director
- 13-12-2016 Mandate renewed· Director
-
Current13-12-2016 → present
-
SA Société d'Investissement et de Participation du Bassin de LiègeLegal entityDirector· perm. rep.: Françoise LeblancState Gazette act 16170400 (13-12-2016)Current13-12-2016 → present
-
Current13-12-2016 → present
-
Current02-05-2016 → present
3 events
- 03-07-2025 Mandate renewed· Director
- 13-12-2016 Mandate renewed· Director
- 02-05-2016 Appointed· Director
Former directors (3)
-
Qbic Venture Partners IILegal entityDirector· perm. rep.: Jean Van NuwenborgState Gazette act 23046123 (04-04-2023)Former27-09-2019 → 14-07-2022
3 events
- 14-07-2022 Resigned· Director
- 14-07-2022 Appointed· Director
- 27-09-2019 Mandate renewed· Director
-
Former— → 13-12-2016
-
Sprl OUSIALegal entityDirector· perm. rep.: Marc FoidartState Gazette act 16170400 (13-12-2016)Former— → 13-12-2016
Full appointment history from the Belgian State Gazette. Permanent representatives are shown for corporate directors.
Statutory auditor
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| BDO EXPERTS COMPTABLES & CONSEILLERS FISCAUXCurrent Statutory auditor · represented by Cédric ANTONELLI |
— | 20-11-2023 → present |
Appointed statutory auditor from the Belgian State Gazette. The IRE/IBR number refers to the register of the Institute of Registered Auditors.
Legal Structure
| NACE primary | 72101 |
| Legal form | Public limited company(014) |
| Incorporation | 20-12-2012 |
| Status | Active |
| Postal code | 4102 |
Connections & network
Group structure
Parent · 3 subsidiaries · 1 location
Control→
Parent · 26 subsidiaries · 2 locations
Control→
Parent · 11 subsidiaries · 2 locations
Control→
Network connections
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Shared corporate director
→
Connections derived from shared directors, addresses, shareholders and group structure in the Belgian State Gazette.
Establishment units
Rue Louis Plescia 9, 4102 Seraing
since 20122.218.862.726
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Real-estate footprint
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates — not a deeds register.
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62343C0011/00S005 | Wallonia | 13.5 ha | — | — |
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data — this is not proof of ownership.
Updates
A single timeline of everything that happened to this company — publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
2026
28-04-2026
State Gazette act
Capital & shares
28-04-2026
State Gazette act
Capital & shares
2025
18-11-2025
State Gazette act
Director changes
18-11-2025
State Gazette act
Director changes
18-11-2025
State Gazette act
Director changes
28-07-2025
NBB filing
Annual accounts filed
2024
17-07-2024
NBB filing
Annual accounts filed
2023
23-11-2023
State Gazette act
Capital & shares
23-11-2023
State Gazette act
Statutes amendment
23-11-2023
State Gazette act
Statutes amendment
23-11-2023
State Gazette act
Capital & shares
23-11-2023
State Gazette act
Director changes
23-11-2023
State Gazette act
Capital & shares
23-11-2023
State Gazette act
Director changes
28-06-2023
NBB filing
Annual accounts filed
04-04-2023
State Gazette act
Director changes
04-04-2023
State Gazette act
Director changes
04-04-2023
State Gazette act
Director changes
24-01-2023
State Gazette act
Capital & shares
24-01-2023
State Gazette act
Statutes amendment
24-01-2023
State Gazette act
Statutes amendment
24-01-2023
State Gazette act
Director changes
24-01-2023
State Gazette act
Capital & shares
24-01-2023
State Gazette act
Director changes
24-01-2023
State Gazette act
Director changes
2022
23-08-2022
NBB filing
Annual accounts filed
23-05-2022
State Gazette act
Registered-office change
23-05-2022
State Gazette act
Registered-office change
23-05-2022
State Gazette act
Registered-office change
2021
27-12-2021
State Gazette act
Capital & shares
27-12-2021
State Gazette act
Statutes amendment
27-12-2021
State Gazette act
Director changes
27-12-2021
State Gazette act
Director changes
27-12-2021
State Gazette act
Statutes amendment
27-12-2021
State Gazette act
Capital & shares
31-08-2021
NBB filing
Annual accounts filed
30-04-2021
State Gazette act
Statutes amendment
30-04-2021
State Gazette act
Capital & shares
30-04-2021
State Gazette act
Capital & shares
30-04-2021
State Gazette act
Statutes amendment
2020
31-08-2020
NBB filing
Annual accounts filed
2019
25-11-2019
State Gazette act
Director changes
25-11-2019
State Gazette act
Director changes
25-11-2019
State Gazette act
Capital & shares
25-11-2019
State Gazette act
Miscellaneous
25-11-2019
State Gazette act
Statutes amendment
25-11-2019
State Gazette act
Capital & shares
25-11-2019
State Gazette act
Capital & shares
25-11-2019
State Gazette act
Statutes amendment
25-11-2019
State Gazette act
Capital & shares
12-09-2019
State Gazette act
Miscellaneous
23-07-2019
NBB filing
Annual accounts filed
13-06-2019
State Gazette act
Director changes
13-06-2019
State Gazette act
Statutes amendment
13-06-2019
State Gazette act
Capital & shares
13-06-2019
State Gazette act
Capital & shares
13-06-2019
State Gazette act
Director changes
13-06-2019
State Gazette act
Statutes amendment
2018
31-08-2018
NBB filing
Annual accounts filed
10-07-2018
State Gazette act
Director changes
10-07-2018
State Gazette act
Capital & shares
10-07-2018
State Gazette act
Director changes
10-07-2018
State Gazette act
Capital & shares
2017
29-09-2017
NBB filing
Annual accounts filed
2016
13-12-2016
State Gazette act
Director changes
13-12-2016
State Gazette act
Director changes
02-08-2016
NBB filing
Annual accounts filed
08-07-2016
State Gazette act
Capital & shares
08-07-2016
State Gazette act
Statutes amendment
08-07-2016
State Gazette act
Capital & shares
08-07-2016
State Gazette act
Statutes amendment
06-05-2016
State Gazette act
Capital & shares
06-05-2016
State Gazette act
Capital & shares
02-05-2016
State Gazette act
Director changes
02-05-2016
State Gazette act
Director changes
2015
18-05-2015
State Gazette act
Registered-office change
18-05-2015
State Gazette act
Registered-office change
Belgisch Staatsblad — acts
Capital history · 23
28-04-2026
v3.2
28-04-2026
Capital change
23-11-2023
v3.2
23-11-2023
Capital change
23-11-2023
v3.2
24-01-2023
v3.2
24-01-2023
v3.2
27-12-2021
v3.2
27-12-2021
v3.2
30-04-2021
v3.2
30-04-2021
v3.2
25-11-2019
v3.2
25-11-2019
v3.2
25-11-2019
v3.2
25-11-2019
v3.2
Address history · 5
23-05-2022
Registered-office move
23-05-2022
v3.2
23-05-2022
Registered-office move
18-05-2015
Registered-office move
18-05-2015
v3.2
All acts · 67
updated 2 months ago
2026
28-04-2026 Capital decrease of €12,975,077.13 to €11,872,836.37
- €24.847.913,50 → €11.872.836,37
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_decrease",
"after_eur": 11872836.37,
"delta_eur": -12975077.13,
"before_eur": 24847913.5,
"contribution_type": null
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
}
}28-04-2026 Capital decrease of €19,033,744 to €24,847,913.50
- €43.881.657,50 → €24.847.913,50
- 10 kapitaalbewegingen in deze akte
Notary:
Quentin PIRET · Tilleur
Technical details
{
"events": [
{
"kind": "capital_decrease",
"after_eur": 11872836.37,
"delta_eur": -12975077.13,
"before_eur": 24847913.5,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": 5650039,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
},
{
"kind": "capital_increase",
"after_eur": 2567500.0,
"delta_eur": 1967500.0,
"before_eur": 600000.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 5135000.0,
"delta_eur": 2567500.0,
"before_eur": 2567500.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 9242750.0,
"delta_eur": 4107750.0,
"before_eur": 5135000.0,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": "C",
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_decrease",
"after_eur": 7936208.77,
"delta_eur": -1306541.23,
"before_eur": 9242750.0,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 11840941.5,
"delta_eur": 3904732.73,
"before_eur": 7936208.77,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": "C",
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 27911299.5,
"delta_eur": 15970358.0,
"before_eur": 11940941.5,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": "D",
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_increase",
"after_eur": 43881657.5,
"delta_eur": 15970358.0,
"before_eur": 27911299.5,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": "D",
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": null,
"contribution_type": "inschrijvingsrechten_uitgifte",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_decrease",
"after_eur": 24847913.5,
"delta_eur": -19033744.0,
"before_eur": 43881657.5,
"share_emission": {
"agio_eur": null,
"share_form": null,
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": null
},
{
"kind": "capital_decrease",
"after_eur": 11872836.37,
"delta_eur": -12975077.13,
"before_eur": 24847913.5,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": 5650039,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
}
],
"notary": {
"name": "Quentin PIRET",
"firm_city": null,
"firm_name": null,
"office_city": "Tilleur",
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2026-04-28",
"filing_date": "2026-04-24",
"act_kind_objet": "Objet de l\u0027acte : CAPITAL, ACTIONS"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2026-04-24",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": null,
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"expedition",
"statuts coordonn\u00E9s"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 1338084,
"class_name": "A",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 183333,
"class_name": "B",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 966530,
"class_name": "C",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 3162092,
"class_name": "D",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}2025
18-11-2025 3 directors appointed, 3 reappointed
- Pierre BELICHARD — Bestuurder
- Robert TAUB — Bestuurder
- Jean-Philippe COMBAL — Bestuurder
- Marc FOIDART — Bestuurder
- Jean-Marie RAKIC — Bestuurder
- Eric BRANDT — Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Pierre BELICHARD",
"address": null,
"birth_date": null
},
"effective_date": "2025-04-23",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale nomme, \u00E0 la majorit\u00E9 des voix \u00E9mises, Monsieur Pierre BELICHARD en qualit\u00E9 d\u0027administrateur ind\u00E9pendant, avec effet au 23 avril 2025."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Robert TAUB",
"address": null,
"birth_date": null
},
"effective_date": "2024-12-15",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale nomme, \u00E0 la majorit\u00E9 des voix \u00E9mises, Monsieur Robert TAUB en qualit\u00E9 d\u0027administrateur de classe C, avec effet au 15 d\u00E9cembre 2024."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean-Philippe COMBAL",
"address": null,
"birth_date": null
},
"effective_date": "2025-07-03",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale nomme, \u00E0 la majorit\u00E9 des voix \u00E9mises Monsieur Jean-Philippe COMBAL en qualit\u00E9 d\u0027administrateur ind\u00E9pendant, avec effet \u00E0 ce jour."
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Marc FOIDART",
"address": null,
"birth_date": null
},
"effective_date": "2025-07-03",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide, \u00E0 la majorit\u00E9 des voix \u00E9mises, de renouveler les mandats de Monsieur Marc FOIDART en qualit\u00E9 d\u0027administrateur de classe A ... et ce avec effet \u00E0 ce jour."
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean-Marie RAKIC",
"address": null,
"birth_date": null
},
"effective_date": "2025-07-03",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide, \u00E0 la majorit\u00E9 des voix \u00E9mises, de renouveler les mandats de ... Monsieur Jean-Marie RAKIC en qualit\u00E9 d\u0027administrateur de classe A ... et ce avec effet \u00E0 ce jour."
},
{
"kind": "director_renew",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Eric BRANDT",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "NOSHAQ SA",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2025-07-03",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide, \u00E0 la majorit\u00E9 des voix \u00E9mises, de renouveler les mandats de ... la SA NOSHAQ en qualit\u00E9 d\u0027administrateur de classe B, et ce avec effet \u00E0 ce jour."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
}
}18-11-2025 4 directors appointed, 3 resigning
- Mélanie MESTDAGT — Ceo
- Pierre BELICHARD — Administrateur indépendant
- Robert TAUB — Administrateur de classe c
- Jean-Philippe COMBAL — Administrateur indépendant
- François MEURGEY — Administrateur indépendant
- Sofie BAETEN — Administrateur de classe c
- Carolyn MYERS — Administrateur indépendant
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_in",
"role": "CEO",
"person": {
"rrn": null,
"name": "M\u00E9lanie MESTDAGT",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Fran\u00E7ois MEURGEY",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Administrateur de classe C",
"person": {
"rrn": null,
"name": "Sofie BAETEN",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Pierre BELICHARD",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Administrateur de classe C",
"person": {
"rrn": null,
"name": "Robert TAUB",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Carolyn MYERS",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "Administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Jean-Philippe COMBAL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
}
}18-11-2025 4 directors appointed, 3 resigning, 3 reappointed
- Mélanie MESTDAGT — Directeur
- Pierre BELICHARD — Directeur
- Robert TAUB — Directeur
- Mélanie MESTDAGT — Dagelijks bestuur
- François MEURGEY — Directeur
- Sofie BAETEN — Directeur
- Carolyn MYERS — Directeur
- Marc FOIDART — Directeur
Technical details
{
"events": [
{
"kind": "director_in",
"role": "directeur",
"person": {
"rrn": null,
"name": "M\u00E9lanie MESTDAGT",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": null,
"statutory": "statutair",
"compensated": null,
"effective_date": "2024-03-01",
"evidence_quote": "Nomination d\u0027un nouveau CEO avec d\u00E9l\u00E9gation \u00E0 la gestion journali\u00E8re",
"decharge_status": null,
"mandate_duration": {
"kind": "indefinite",
"value": null
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "future"
},
{
"kind": "director_out",
"role": "directeur",
"person": {
"rrn": null,
"name": "Fran\u00E7ois MEURGEY",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": "de_plein_droit_dissolution",
"subkind": "regular",
"via_org": {
"kbo": null,
"name": "SRL OUKELOS",
"address": null,
"country": null,
"legal_form": "SRL"
},
"statutory": "statutair",
"compensated": null,
"effective_date": "2025-04-22",
"evidence_quote": "D\u00E9mission de la SRL OUKELOS (administrateur ind\u00E9pendant, repr\u00E9sent\u00E9 de mani\u00E8re permanente par Fran\u00E7ois MEURGEY)",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_out",
"role": "directeur",
"person": {
"rrn": null,
"name": "Sofie BAETEN",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": "de_plein_droit_dissolution",
"subkind": "regular",
"via_org": {
"kbo": null,
"name": "SA QBIC VENTURE PARTNERS II",
"address": null,
"country": null,
"legal_form": "SA"
},
"statutory": "statutair",
"compensated": null,
"effective_date": "2024-12-15",
"evidence_quote": "D\u00E9mission de la SA QBIC VENTURE PARTNERS II (Administrateur de classe C, repr\u00E9sent\u00E9 de mani\u00E8re permanente par Sofie BAETEN)",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_in",
"role": "directeur",
"person": {
"rrn": null,
"name": "Pierre BELICHARD",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "confirmation",
"via_org": null,
"statutory": "coopted",
"compensated": null,
"effective_date": "2025-04-23",
"evidence_quote": "Confirmation de la nomination de Monsieur Pierre BELICHARD en sa qualit\u00E9 d\u0027administrateur ind\u00E9pendant",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": 4
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "future"
},
{
"kind": "director_in",
"role": "directeur",
"person": {
"rrn": null,
"name": "Robert TAUB",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "confirmation",
"via_org": null,
"statutory": "coopted",
"compensated": null,
"effective_date": "2024-12-15",
"evidence_quote": "Confirmation de la nomination de Monsieur Robert TAUB en sa qualit\u00E9 d\u0027administrateur de classe C",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": 4
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "future"
},
{
"kind": "director_out",
"role": "directeur",
"person": {
"rrn": null,
"name": "Carolyn MYERS",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": "de_plein_droit_dissolution",
"subkind": "regular",
"via_org": null,
"statutory": "statutair",
"compensated": null,
"effective_date": "2025-06-24",
"evidence_quote": "Remplacement de Madame Carolyn MYERS par Monsieur Jean-Philippe COMBAL au titre d\u0027administrateur ind\u00E9pendant",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_renew",
"role": "directeur",
"person": {
"rrn": null,
"name": "Marc FOIDART",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "renewal",
"via_org": null,
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "Renouvellement des mandats d\u0027administrateur de Monsieur Marc FOIDART (classe A)",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": 4
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "director_renew",
"role": "directeur",
"person": {
"rrn": null,
"name": "Jean-Marie RAKIC",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "renewal",
"via_org": null,
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "Renouvellement des mandats d\u0027administrateur de Monsieur Jean-Marie RAKIC (classe A)",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": 4
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "director_renew",
"role": "directeur",
"person": {
"rrn": null,
"name": "Eric BRANDT",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "renewal",
"via_org": {
"kbo": null,
"name": "NOSHAQ SA",
"address": null,
"country": null,
"legal_form": "SA"
},
"statutory": "statutair",
"compensated": null,
"effective_date": null,
"evidence_quote": "Renouvellement des mandats d\u0027administrateur de ... NOSHAQ SA (classe B, repr\u00E9sent\u00E9 de mani\u00E8re permanente par Eric BRANDT)",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": 4
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": "immediate"
},
{
"kind": "delegation_dagelijks_bestuur_in",
"role": "delegated_daily_management",
"person": {
"rrn": null,
"name": "M\u00E9lanie MESTDAGT",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "regular",
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale mandate Madame M\u00E9lanie MESTDAGT pour proc\u00E9der aux publications requises.",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2025-11-18",
"filing_date": "2025-11-06",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [
{
"body": "conseil_d_administration",
"date": "2024-02-20",
"unanimous": true
},
{
"body": "assembl\u00E9e_generale_ordinaire",
"date": "2025-07-03",
"unanimous": null
}
],
"is_correction": false,
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA",
"_kbo_filled_from_list": true
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "M\u00E9lanie MESTDAGT",
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [],
"corrected_publication_numac": null
}2023
23-11-2023 Capital decrease of €19,033,744 to €24,847,913.50
- €43.881.657,50 → €24.847.913,50
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_decrease",
"amount": 19033744.0,
"currency": "EUR",
"after_eur": 24847913.5,
"delta_eur": -19033744.0,
"before_eur": 43881657.5,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-11-20",
"evidence_quote": "L\u2019Assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide, \u00E0 l\u2019unanimit\u00E9, de r\u00E9duire le capital \u00E0 concurrence de dix neuf millions trente-trois mille sept cent quarante-quatre euros (19.033.744,00 \u20AC), par incorporation, en vue d\u2019apurer \u00E0 concurrence du m\u00EAme montant, les pertes subies figurant \u00E0 la situation comptable arr\u00EAt\u00E9e au 31 d\u00E9cembre 2022... En cons\u00E9quence, le capital est port\u00E9 de quarante-trois millions huit cent quatre-vingt-un mille six cent cinquante-sept euros cinquante centimes (43.881.657,50 \u20AC) \u00E0 vingt-quatre millions huit cent quarante-sept mille neuf cent treize euros cinquante centimes (24.847.913,50 \u20AC).",
"contribution_type": "in_kind"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
}
}23-11-2023 Articles of association amended
Summary:
v3.2
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}23-11-2023 Articles of association amended
Summary:
v3.2
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2023-11-20",
"legal_form_change": false
},
"bedrijfsrevisor": {
"quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de nommer, \u00E0 la fonction de commissaire, la soci\u00E9t\u00E9 BDO EXPERTS COMPTABLES \u0026 CONSEILLERS FISCAUX, en abr\u00E9g\u00E9 BDO Experts Comptables, dont le si\u00E8ge est situ\u00E9 \u00E0 1930 Zaventem, Da Vincilaan 9 bo\u00EEte E.6, avec un si\u00E8ge d\u2019exploitation \u00E0 4651 Herve (Battice), Rue Waucomont 51, repr\u00E9sent\u00E9e par Monsieur C\u00E9dric ANTONELLI, pour une dur\u00E9e de 3 ans, renouvelable.",
"firm_kbo": null,
"firm_name": "BDO EXPERTS COMPTABLES \u0026 CONSEILLERS FISCAUX",
"ibr_number": null,
"individual_name": "C\u00E9dric ANTONELLI"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
},
"signature_regime": null,
"special_mandates": [
{
"quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale conf\u00E8re au notaire soussign\u00E9 tous pouvoirs n\u00E9cessaires aux fins de coordonner les statuts.",
"holder_kbo": null,
"holder_name": "notaire soussign\u00E9",
"scope_categories": [
"publication",
"coordination"
],
"with_substitution": false
},
{
"quote": "L\u2019assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Monsieur Marc FOIDART pour l\u2019ex\u00E9cution des r\u00E9solutions \u00E0 prendre sur les objets qui pr\u00E9c\u00E8dent.",
"holder_kbo": null,
"holder_name": "Marc FOIDART",
"scope_categories": [
"execution"
],
"with_substitution": false
}
],
"governance_change": {
"admin_delegated_added": []
}
}23-11-2023 Capital decrease of €19,033,744 to €24,847,913.50
- €43.881.657,50 → €24.847.913,50
Notary:
Manon DEPREZ · Tilleur
Technical details
{
"events": [
{
"kind": "capital_decrease",
"after_eur": 24847913.5,
"delta_eur": -19033744.0,
"before_eur": 43881657.5,
"share_emission": {
"agio_eur": null,
"share_form": "no_nominal_value",
"share_class": null,
"n_new_shares": null,
"with_new_shares": false,
"nominal_value_eur": null,
"issue_price_per_share_eur": null
},
"decrease_purpose": "loss_absorption",
"contribution_type": null,
"paid_up_delta_eur": null,
"n_shares_destroyed": 5650039,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "convert_to_apports_non_appeles"
}
],
"notary": {
"name": "Manon DEPREZ",
"firm_city": null,
"firm_name": null,
"office_city": "Tilleur",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2023-11-23",
"filing_date": "2023-11-21",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2023-11-20",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": null
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Quentin PIRET",
"org_rep_person_name": null,
"person_role_at_subject": "notaire"
},
"co_filed_documents": [
"expedition",
"statuts coordonn\u00E9s"
],
"shareholders_after": [],
"share_classes_after": [
{
"n_shares": 1338084,
"class_name": "A",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 183333,
"class_name": "B",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 966530,
"class_name": "C",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
},
{
"n_shares": 3162092,
"class_name": "D",
"capital_share_eur": null,
"voting_rights_per_share": 1.0
}
]
}23-11-2023 3 directors appointed, 1 resigning
- BDO Experts Comptables — Commissaire
- FUND+ — Administrateur de classe c
- Bert DE LEEUW — Représentant permanent de fund+
- Lawrence VAN HELLEPUTTE — Représentant permanent de l'administrateur « fund+ »
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "BDO Experts Comptables",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur de classe C",
"person": {
"rrn": null,
"name": "FUND\u002B",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "repr\u00E9sentant permanent de l\u0027administrateur \u00AB FUND\u002B \u00BB",
"person": {
"rrn": null,
"name": "Lawrence VAN HELLEPUTTE",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "repr\u00E9sentant permanent de FUND\u002B",
"person": {
"rrn": null,
"name": "Bert DE LEEUW",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
}
}23-11-2023 Capital decrease of €19,033,744 to €24,847,913.50
- €43.881.657,50 → €24.847.913,50
- Inbreng in geld · Apport en numéraire
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_decrease",
"after_eur": 24847913.5,
"delta_eur": -19033744.0,
"before_eur": 43881657.5,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
}
}23-11-2023 2 directors appointed
- Cédric ANTONELLI — Commissaris
- Bert DE LEEUW — Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "C\u00E9dric ANTONELLI",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "BDO EXPERTS COMPTABLES \u0026 CONSEILLERS FISCAUX",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "En suite de quoi l\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de nommer, \u00E0 la fonction de commissaire, la soci\u00E9t\u00E9 BDO EXPERTS COMPTABLES \u0026 CONSEILLERS FISCAUX, en abr\u00E9g\u00E9 BDO Experts Comptables, dont le si\u00E8ge est situ\u00E9 \u00E0 1930 Zaventem, Da Vincilaan 9 bo\u00EEte E.6, avec un si\u00E8ge d\u2019exploitation \u00E0 4651 Herve (Battice), Rue"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Bert DE LEEUW",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0629896521",
"name": "FUND\u002B",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "La Soci\u00E9t\u00E9 Anonyme \u00AB FUND\u002B \u00BB, ayant son si\u00E8ge \u00E0 3000 Louvain, Groot Begijnhof 60, bo\u00EEte 1, reprise au registre des personnes morales sous le num\u00E9ro 0629.896.521, pour laquelle Monsieur Bert DE LEEUW, domicili\u00E9 \u00E0 8930 Lauwe (Menen) Weggevoerdenlaan 4 est d\u00E9sign\u00E9 comme repr\u00E9sentant permanent."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
}
}04-04-2023 1 director appointed, 1 resigning
- Sofie Baeten — Administrateur de classe c
- Jean Van Nuwenborg — Administrateur de classe c
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_in",
"role": "Administrateur de Classe C",
"person": {
"rrn": null,
"name": "Sofie Baeten",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "Administrateur de Classe C",
"person": {
"rrn": null,
"name": "Jean Van Nuwenborg",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "Eyed Pharma"
}
}04-04-2023 Permanent representative changed: Sofie Baeten succeeds Jean Van Nuwenborg
Technical details
{
"events": [
{
"kind": "rep_rotation",
"role": "vaste_vertegenwoordiger",
"person": {
"rrn": null,
"name": "Sofie Baeten",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": "successor_conditional",
"via_org": {
"kbo": "0668.403.244",
"name": "Qbic Venture Partner II NV",
"address": "Hekers 3, 9051 Zwijnaarde",
"country": "BE",
"legal_form": "NV"
},
"statutory": null,
"compensated": null,
"effective_date": "2022-07-14",
"evidence_quote": "La repr\u00E9sentante permanente de l\u0027Administrateur de classe C Qbic Venture Partner II NV, Hekers 3, 9051 Zwijnaarde avec le num\u00E9ro d\u0027entreprise 0668.403.244, devient \u00E0 partir du 14 juillet 2022, Mme Sofie Baeten, en remplacement de M. Jean Van Nuwenborg.",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": "Sofie Baeten",
"rep_rotation_old_rep": "Jean Van Nuwenborg",
"effective_date_qualifier": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": "LIEGE",
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2023-04-04",
"filing_date": "2023-03-24",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [],
"is_correction": false,
"subject_company": {
"kbo": "0508.599.605",
"name_full": "Eyed Pharma",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "M\u00E9lanie MESTDAGT",
"org_rep_person_name": null,
"person_role_at_subject": "repr\u00E9sentant permanent"
},
"co_filed_documents": [],
"corrected_publication_numac": null
}04-04-2023 1 director appointed, 1 resigning
- Sofie Baeten — Bestuurder
- Jean Van Nuwenborg — Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Jean Van Nuwenborg",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0668403244",
"name": "Qbic Venture Partner II NV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2022-07-14",
"evidence_quote": "La repr\u00E9sentante permanente de l\u0027Administrateur de classe C Qbic Venture Partner II NV, Hekers 3, 9051 Zwijnaarde avec le num\u00E9ro d\u0027entreprise 0668.403.244, devient \u00E0 partir du 14 juillet 2022, Mme Sofie Baeten, en remplacement de M. Jean Van Nuwenborg."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Sofie Baeten",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0668403244",
"name": "Qbic Venture Partner II NV",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2022-07-14",
"evidence_quote": "La repr\u00E9sentante permanente de l\u0027Administrateur de classe C Qbic Venture Partner II NV, Hekers 3, 9051 Zwijnaarde avec le num\u00E9ro d\u0027entreprise 0668.403.244, devient \u00E0 partir du 14 juillet 2022, Mme Sofie Baeten, en remplacement de M. Jean Van Nuwenborg."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
}
}24-01-2023 Capital increase of €15,970,358 to €43,881,657.50
- €27.911.299,50 → €43.881.657,50
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_increase",
"amount": 15970358,
"currency": "EUR",
"after_eur": 43881657.5,
"delta_eur": 15970358.0,
"before_eur": 27911299.5,
"amount_type": "kapitaal_effectief",
"effective_date": "2023-01-20",
"evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide ensuite d\u2019augmenter le capital social \u00E0 concurrence de quinze millions neuf cent septante mille trois cent cinquante-huit euros (15.970.358 \u20AC) pour porter celui-ci de vingt-sept millions neuf cent onze mille deux cent nonante-neuf euros cinquante centimes (27.911.299,50 \u20AC), \u00E0 quarante-trois millions huit cent quatre-vingt-un mille six cent cinquante-sept euros cinquante centimes (43.881.657,50 \u20AC)",
"contribution_type": "cash"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
}
}24-01-2023 Articles of association amended
Summary:
v3.2
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
},
"legal_form_change": {
"new": "",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}24-01-2023 Articles of association amended
Summary:
v3.2
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2023-01-20",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}24-01-2023 3 directors appointed
- Lawrence VAN HELLEPUTTE — Bestuurder
- Mélanie MESTDAGT
- Carolyn MYERS
Notary:
Manon DEPREZ · Tilleur
Technical details
{
"events": [
{
"kind": "decharge_granted",
"role": null,
"person": null,
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "Elle lui donne d\u00E9charge pour l\u2019exercice de son mandat",
"decharge_status": "granted",
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Lawrence VAN HELLEPUTTE",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": {
"kbo": "0629.896.521",
"name": "FUND\u002B",
"address": "Groot Begijnhof 60, bo\u00EEte 1, 3000 Louvain",
"country": "BE",
"legal_form": "SA"
},
"statutory": null,
"compensated": false,
"effective_date": null,
"evidence_quote": "La Soci\u00E9t\u00E9 Anonyme \u00AB FUND\u002B \u00BB, ayant son si\u00E8ge \u00E0 3000 Louvain, Groot Begijnhof 60, bo\u00EEte 1,",
"decharge_status": null,
"mandate_duration": {
"kind": "n_years",
"value": "4"
},
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_in",
"role": null,
"person": {
"rrn": null,
"name": "M\u00E9lanie MESTDAGT",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "l\u2019assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Madame M\u00E9lanie MESTDAGT pour l\u2019ex\u00E9cution des r\u00E9solutions",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "director_in",
"role": null,
"person": {
"rrn": null,
"name": "Carolyn MYERS",
"address": null,
"birth_date": null,
"profession": null,
"birth_place": null
},
"reason": null,
"subkind": null,
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "l\u2019assembl\u00E9e g\u00E9n\u00E9rale conf\u00E8re au notaire soussign\u00E9 tous pouvoir pour effectuer la publication de la nomination de Madame Carolyn MYERS",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
},
{
"kind": "correction",
"role": null,
"person": null,
"reason": null,
"subkind": "rectification",
"via_org": null,
"statutory": null,
"compensated": null,
"effective_date": null,
"evidence_quote": "",
"decharge_status": null,
"mandate_duration": null,
"rep_rotation_new_rep": null,
"rep_rotation_old_rep": null,
"effective_date_qualifier": null
}
],
"notary": {
"name": "Manon DEPREZ",
"firm_city": null,
"firm_name": null,
"office_city": "Tilleur",
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2023-01-24",
"filing_date": "2023-01-20",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decisions": [
{
"body": "buitengewone_algemene_vergadering",
"date": "2023-01-20",
"unanimous": true
}
],
"is_correction": false,
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Quentin PIRET",
"org_rep_person_name": null,
"person_role_at_subject": "notaire associ\u00E9"
},
"co_filed_documents": [
"une exp\u00E9dition de l\u0027acte",
"les statuts coordonn\u00E9s",
"les rapports dans le cadre de l\u0027augmentation de capital et l\u0027\u00E9mission des droits de souscription"
],
"corrected_publication_numac": null
}24-01-2023 Capital increase of €15,970,358 to €43,881,657.50
- €27.911.299,50 → €43.881.657,50
- Inbreng in geld · Apport en numéraire
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 43881657.5,
"delta_eur": 15970358.0,
"before_eur": 27911299.5,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
}
}24-01-2023 1 director appointed, 1 resigning
- Fund+ — Administrateur de classe c
- Pienter-Jan — Administrateur de classe c
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur de classe C",
"person": {
"rrn": null,
"name": "Pienter-Jan",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur de classe C",
"person": {
"rrn": null,
"name": "Fund\u002B",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
}
}24-01-2023 Lawrence VAN HELLEPUTTE appointed as director
- Lawrence VAN HELLEPUTTE — Bestuurder
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Lawrence VAN HELLEPUTTE",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0629896521",
"name": "Soci\u00E9t\u00E9 Anonyme \u00AB FUND\u002B \u00BB",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide en cons\u00E9quence de proc\u00E9der \u00E0 la nomination, en qualit\u00E9 d\u2019 administrateur de classe C : \u2022 La Soci\u00E9t\u00E9 Anonyme \u00AB FUND\u002B \u00BB, ayant son si\u00E8ge \u00E0 3000 Louvain, Groot Begijnhof 60, bo\u00EEte 1, reprise au registre des personnes morales sous le num\u00E9ro 0629.896.521, pour laquelle Monsieu"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
}
}2022
23-05-2022 Registered office moved from Liège to Seraing
- Avenue Hippocrate, 5-4000 Liège → rue Louis Plescia, 9 à 4102 Seraing (Ougrée)
Notary:
M. Jean-Pierre Dupont · Liège
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "rue Louis Plescia, 9 \u00E0 4102 Seraing (Ougr\u00E9e)",
"city": "Seraing",
"region": "waals_gewest",
"street": "rue Louis Plescia",
"country": "BE",
"postcode": "4102",
"box_number": null,
"street_number": "9",
"locality_suffix": "(Ougr\u00E9e)"
},
"old_address": {
"raw": "Avenue Hippocrate, 5-4000 Li\u00E8ge",
"city": "Li\u00E8ge",
"region": "waals_gewest",
"street": "Avenue Hippocrate",
"country": "BE",
"postcode": "4000",
"box_number": null,
"street_number": "5",
"locality_suffix": null
},
"effective_date": "2022-03-24",
"evidence_quote": "En sa s\u00E9ance du 24 mars 2022, le conseil d\u0027administration a d\u00E9cid\u00E9, \u00E0 l\u0027unanimit\u00E9, de transf\u00E9rer le si\u00E8ge de la soci\u00E9t\u00E9 \u00E0 l\u0027adresse suivante: rue Louis Plescia, 9 \u00E0 4102 Seraing (Ougr\u00E9e).",
"region_changed": false,
"is_statute_change": false,
"nationality_change": false,
"old_address_source": "act_body",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "absolute",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": "M. Jean-Pierre Dupont",
"firm_city": null,
"firm_name": null,
"office_city": "Li\u00E8ge",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2022-05-23",
"filing_date": "2022-03-24",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "raad_van_bestuur",
"date": "2022-03-24",
"unanimous": true
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "Eyed Pharma",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "M\u00E9lanie Mestdagt",
"org_rep_person_name": null,
"person_role_at_subject": "mandataire"
},
"co_filed_documents": [
"D\u00E9claration de transfert de si\u00E8ge social",
"Proc\u00E8s-verbal du conseil d\u0027administration du 24 mars 2022",
"Pouvoirs de repr\u00E9sentation pour les formalit\u00E9s"
]
}23-05-2022 Registered office moved from Liège to Seraing
- Avenue Hippocrate 5, 4000 Liège → rue Louis Plescia 9, 4102 Seraing
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "statutaire",
"new_address": {
"city": "Seraing",
"region": null,
"street": "rue Louis Plescia",
"country": "BE",
"postcode": "4102",
"box_number": null,
"street_number": "9"
},
"old_address": {
"city": "Li\u00E8ge",
"region": null,
"street": "Avenue Hippocrate",
"country": "BE",
"postcode": "4000",
"box_number": null,
"street_number": "5"
},
"effective_date": "2022-03-24",
"evidence_quote": "En sa s\u00E9ance du 24 mars 2022, le conseil d\u0027administration a d\u00E9cid\u00E9, \u00E0 l\u0027unanimit\u00E9, de transf\u00E9rer le si\u00E8ge de la soci\u00E9t\u00E9 \u00E0 l\u0027adresse suivante: rue Louis Plescia, 9 \u00E0 4102 Seraing (Ougr\u00E9e)."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
}
}23-05-2022 Registered office moved to Seraing
- rue Louis Plescia, 9 à 4102 Seraing (Ougrée)
Technical details
{
"events": [
{
"kind": "zetel_transfer_cross_border_in",
"seat_type": "siege_social",
"new_address": {
"raw": "rue Louis Plescia, 9 \u00E0 4102 Seraing (Ougr\u00E9e)",
"city": "Seraing",
"region": "waals_gewest",
"street": "rue Louis Plescia",
"country": "BE",
"postcode": "4102",
"box_number": null,
"street_number": "9",
"locality_suffix": "(Ougr\u00E9e)"
},
"old_address": null,
"effective_date": null,
"evidence_quote": "",
"region_changed": false,
"is_statute_change": true,
"nationality_change": true,
"old_address_source": "act_body",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": null,
"statutaire_vs_werkelijke": null,
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": null
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "mixed",
"pub_date": "2022-05-23",
"filing_date": "2022-03-24",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "conseil_d_administration",
"date": "2022-03-24",
"unanimous": true
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "FRILUNAL OF L\u0027ENTEPRISE DE LIEGE",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "M\u00E9lanie MESTDAGT",
"org_rep_person_name": null,
"person_role_at_subject": "mandataire"
},
"co_filed_documents": []
}2021
27-12-2021 Capital increase of €15,970,358 to €27,911,299.50
- €11.940.941,50 → €27.911.299,50
- Inbreng in geld · Apport en numéraire
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 27911299.5,
"delta_eur": 15970358.0,
"before_eur": 11940941.5,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
}
}27-12-2021 Articles of association amended
Summary:
v3.2
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}27-12-2021 3 directors appointed, 1 resigning
- Société Anonyme SPARAXIS — Administrateur de classe d
- Société Anonyme CORPAR — Administrateur de classe d
- REWISE AD REVISEUR D'ENTREPRISES SRL — Commissaire
- Denis KNOOPS — Administrateur indépendant
Summary:
v3.2
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Denis KNOOPS",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur de classe D",
"person": {
"rrn": null,
"name": "Soci\u00E9t\u00E9 Anonyme SPARAXIS",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur de classe D",
"person": {
"rrn": null,
"name": "Soci\u00E9t\u00E9 Anonyme CORPAR",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "REWISE AD REVISEUR D\u0027ENTREPRISES SRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA"
}
}27-12-2021 Change in the board of directors
Summary:
v3.2
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
}
}27-12-2021 Articles of association amended
Summary:
v3.2
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2021-12-20",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0508.599.605",
"name_full": "EYED PHARMA",
"legal_form": "SA"
},
"signature_regime": "joint_two",
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}First 30 of 67 acts
Credit advice
AI due-diligence brief
Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Coming soon
AI-generated from Checked data; indicative, not legal or investment advice.
Company registry (CBE)
Activities
Speur- en ontwikkelingswerk op biotechnologisch gebied72101Speur- en ontwikkelingswerk op biotechnologisch gebied72110
Primary activity highlighted.
Names & trade names
| Legal nameFR | EYED PHARMA |
Registered office
Rue Louis Plescia 9
4102 Seraing, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.
Similar companies
Biocubik
BE 0782.955.294 · Seraing
Greenewable Consulting & Management
BE 0797.048.505 · Seraing
AQUILON PHARMACEUTICALS
BE 0540.870.218 · Seraing
DIAGENODE
BE 0480.422.786 · Seraing
KANEKA EUROGENTEC
BE 0427.348.346 · Seraing